As of April 15, 261 science and technology innovation board listed companies have disclosed the main financial data of 2020 in the form of annual report or performance express. According to wind data, the net profit of 18 shares of Junshi biology, Zejing pharmaceutical and youkede in 2020 is at a loss. Among the 18 stocks with performance losses mentioned above, 14 are enterprises with “U”, and four stocks, such as youkede, are the first losses since they were listed.
The net profit of Shengxiang biology increased by more than 10 times
According to the data disclosed by wind, 243 of the 261 companies listed on the science and technology innovation board remain profitable in 2020, accounting for 93.1% of the total number of companies on the science and technology innovation board.
According to wind data, 136 of the 243 listed companies on the science and technology innovation board achieved a net profit of more than 100 million yuan in 2020, including 17 shares of LanChi technology, Trina Solar, stone technology and Oriental biology, with a net profit of more than 1 billion yuan in 2020. According to the data disclosed by wind, SMIC’s attributable net profit in 2020 is about 4.332 billion yuan, ranking the first in the number of shares on the science and technology innovation board.
The growth rate of attributable net profit is an important indicator to measure the growth status and development ability of an enterprise. According to wind data, among the 243 listed companies with net profit in 2020, 180 companies have a year-on-year growth in net profit. Among them, 29 shares, including Xinhai Technology, Haier biology, Jinshan office, etc., have a year-on-year growth in net profit. Four listed companies with net profit in 2020 have a year-on-year growth in net profit Profits increased by more than 10 times.
The biggest increase was in Shengxiang biology. Data show that in 2020, the net profit of Shengxiang bio is about 2.617 billion yuan, an increase of more than 65 times over the same period last year. The attributable net profits of Shijia photonics, Dongfang biology and Zhijiang biology in 2020 were 39 million yuan, 1.688 billion yuan and 928 million yuan respectively, with a year-on-year growth of 2542.2%, 1956.37% and 1701.53% respectively. In terms of wind industry, Shengxiang biology, Dongfang biology and Zhijiang biology are all health care enterprises.
Wind data statistics show that among the 243 listed companies on the science and technology innovation board, there are still many stocks with net profit falling year on year in 2020. Specifically, the net profit of 24 shares in 2020 fell by more than 30% year on year, including Lexin technology, Minxin shares, Haohai Shengke, etc. In 2020, the net profit attributable to the five shares of Xinguang optoelectronics, sanuo medical, Nuohe Zhiyuan, Ruisheng intelligent and Tianyi Shangjia decreased by more than 50%.
Net profit loss of 14 shares exceeded 100 million yuan
According to wind data, there are 18 listed companies in the science and technology innovation board in 2020, and their net profit is in the state of loss.
Specifically, among the 18 companies listed on the science and technology innovation board, 14 stocks have net profit loss of over 100 million yuan in 2020, including Qingyun technology, frontier biology, Zejing pharmaceutical, etc.
According to the data disclosed by wind, Junshi bio has the largest loss among the 18 companies listed on the science and technology innovation board with net profit loss in 2020. Data show that the net profit loss of Junshi bio in 2020 is about 1.669 billion yuan.
It is understood that Junshi bio will be listed on July 15, 2020 and is an innovation driven biopharmaceutical company. As for the reasons for the performance loss, Junshi Bio said that the main reason is that the company’s operating revenue can not fully cover the continuously increasing R & D investment in research projects and reserve R & D projects. Junshi bio also said that the company has reserved a number of projects in the early stage of preclinical research. In the future, the company will continue to invest in R & D on a large scale to complete product pipeline R & D business such as preclinical research, clinical trials and pre marketing preparation of new drugs. In addition, the company will also bring high costs in new drug listing application and new drug marketing, which are likely to lead to high costs As a result, the company’s losses further expanded.
After Junshi biology is Shenzhou cell, which will achieve a net profit loss of about 713 million yuan in 2020.
It is worth mentioning that according to the statistics of wind, among the 18 listed companies with net profit loss in 2020, 14 are enterprises with “U”, accounting for 77.78% of the number of enterprises with net profit loss in 2020.
According to the industry of wind, among the 18 listed companies with net profit loss in 2020, 9 of them belong to the health care industry, 6 of them belong to the information technology industry, and 3 of them belong to the industrial field.
Economist song Qinghui believes that most of the companies with performance losses in the science and technology innovation board are biomedical innovation companies. From the perspective of the general development cycle, large R & D investment before the product launch and the situation of continuous loss or even no income in the short term are the inevitable pain for the growth of these enterprises.
First loss of 4 shares listed
It is worth noting that youkede, Funeng technology, Sansheng Guojian and Youfang technology will be listed for the first time.
If the companies with “U” are excluded, the performance of youkede is the worst among the 18 listed companies with net profit loss in 2020. According to the 2020 performance express disclosed by youkede, the operating revenue of youkede in 2020 was about 2.466 billion yuan, up 62.79% year on year; the corresponding net profit loss was about 341 million yuan, from profit to loss year on year.
It is understood that youkede, listed on January 20, 2020, is a third-party cloud computing service provider and one of the first batch of enterprises that have passed the trusted cloud service certification. It provides services for users through three modes of public cloud, private cloud and hybrid cloud. This is also the first loss in the annual report of the company after its listing.
As for the specific reasons for the company’s net profit loss in 2020, the relevant person of youkede said in an interview with Beijing business daily, “we are in the silent period of the annual report. The 2020 annual report will be issued on April 27, and the annual report will explain this matter in detail.”.
In addition to youkede, Funeng technology, Sansheng Guojian, Youfang technology also ushered in the first loss. It is understood that Sansheng Guojian will be listed on July 22, 2020, mainly engaged in the R & D, production and sales of antibody drugs. According to the performance express, the net profit loss of Sansheng Guojian in 2020 is about 200 million yuan. Before listing, Sansheng Guojian’s performance remained profitable. According to the data, from 2017 to 2019, the attributable net profit of Sansheng Guojian is about 390 million yuan, 370 million yuan and 230 million yuan respectively.
Funeng technology and Youfang technology will be listed on July 17, 2020 and January 23, 2020 respectively. The net profit of Funeng technology and Youfang technology in 2020 will be about – 316 million yuan and – 69 million yuan respectively.
Xu Xiaoheng, an investment and financing expert, said that investors should be cautious in investing in stocks with “face changing” performance after listing.
Beijing Business Daily reporter Liu Fengru
[the above content is transferred from “Beijing Business Daily website”, which does not represent the view of this website. If you need to reprint it, please get permission from the website of Beijing business daily. If there is any infringement, please contact to delete it. 】